Sugi Predict

Sugi Predict / Compounds / SCHEMBL670944

SCHEMBL670944

SCHEMBL670944

CCOC(=O)c1ccc(C)c(Br)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.59
▸ CA1 P00915 3/20 0.59
▸ CA2 P00918 3/20 0.59
▸ CA7 P43166 3/20 0.59
▸ CA9 Q16790 3/20 0.59
▸ CA14 Q9ULX7 3/20 0.59
▸ HPGD P15428 5/20 0.58
▸ ESR1 P03372 2/20 0.55
▸ ESR2 Q92731 1/20 0.55
▸ MAPT P10636 2/20 0.53
▸ TP53 P04637 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ MAOA P21397 1/20 0.53
▸ HSD17B2 P37059 1/20 0.53
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ HCRTR1 O43613 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30349688 1.00 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL22468902 0.87 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL31700926 0.86 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL137202 0.86 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL19102619 0.85 ESR1 (0.74) HPGDESR1MAPTLMNACYP1A2
SCHEMBL30812164 0.84 ESR1 (0.72) CA12CA1CA2CA7CA9
SCHEMBL2994444 0.84 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL2543424 0.84 ESR1 (0.72) CA12CA1CA2CA7CA9
SCHEMBL16599460 0.84 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL23092251 0.84 RAB9A (0.68) MAPTTP53MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028328-A1 HETEROARYL DERIVATIVES AS DDRs INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2026-01-29 — — US disclosed
EP-4558489-A1 HETEROARYL DERIVATIVES AS DDRs INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2025-05-28 — — EP disclosed
CN-119585248-A Heteroaryl derivatives as DDR inhibitors 奇斯药制品公司 2025-03-07 — — CN disclosed
CN-119562946-A Heteroaryl derivatives as DDR inhibitors 奇斯药制品公司 2025-03-04 — — CN disclosed
US-20240425482-A1 PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-12-26 — — US disclosed
CN-118284601-A Pyrrolidine derivatives as DDR inhibitors 奇斯药制品公司 2024-07-02 — — CN disclosed
WO-2024017877-A1 HETEROARYL DERIVATIVES AS DDRs INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-25 — — WO disclosed
WO-2024017876-A1 HETEROARYL DERIVATIVES AS DDRs INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-25 — — WO disclosed
WO-2023066834-A1 PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-04-27 — — WO disclosed
WO-2023048034-A1 METHOD FOR PRODUCING AROMATIC COMPOUND HAVING ETHYNYL GROUP 東レ・ファインケミカル株式会社 2023-03-30 — — WO disclosed
EP-1701944-A2 2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-09-20 — — EP disclosed
US-20060040968-A1 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. 2006-02-23 — — US disclosed
US-20060014742-A1 Amide derivative NIPPON SHINYAKU CO., LTD. (JP) 2006-01-19 — — US disclosed
WO-2005066139-A2 2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-07-21 — — WO disclosed
EP-1533304-A1 AMIDE DERIVATIVE Nippon Shinyaku Co., Ltd. (JP) 2005-05-25 — — EP disclosed
EP-0683781-B1 NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE METABASIS THERAPEUTICS INC (US) 2004-04-21 — — EP disclosed
US-5731432-A Inhibitors of adenosine monophosphate deaminase GENSIA SICOR INC. (US) 1998-03-24 — — US disclosed
EP-0683781-A4 NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE. GENSIA PHARMA (US) 1997-05-28 — — EP disclosed
EP-0683781-A1 NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE GENSIA PHARMACEUTICALS, INC. (US) 1995-11-29 — — EP disclosed
WO-1994018200-A1 NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE GENSIA, INC. (US) 1994-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425482-A1 PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 CA12 4881/4885CA1 4880/4885CA2 4811/4885
US-20060040968-A1 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases PRKCZ, PRKCQ, PRKCE CA12 4827/4885CA1 4332/4885CA2 2618/4885
US-20060014742-A1 Amide derivative ABL1, ABL2, BCR CA12 4864/4885CA1 4808/4885CA2 3469/4885
US-20260028328-A1 HETEROARYL DERIVATIVES AS DDRs INHIBITORS DDR1, DDR2, DDRGK1 CA12 4810/4885CA1 4545/4885CA2 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.